Unlimited access to the most powerful analytical tools in finance.

Subscribe for $2
Overview
Profile
Akero Therapeutics Stock

Akero Therapeutics Stock AKRO

AKRO
US00973Y1082
A2PLNP

Price

0
Today +/-
-0
Today %
-0 %

Akero Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Akero Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Akero Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Akero Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Akero Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Akero Therapeutics Stock Price History

DateAkero Therapeutics Price
6/6/20250 undefined
6/6/202555.81 undefined
6/5/202553.42 undefined
6/4/202553.00 undefined
6/3/202551.25 undefined
6/2/202551.21 undefined
5/30/202549.82 undefined
5/29/202548.45 undefined
5/28/202545.55 undefined
5/27/202546.36 undefined
5/23/202545.59 undefined
5/22/202550.27 undefined
5/21/202548.36 undefined
5/20/202548.01 undefined
5/19/202538.41 undefined
5/16/202539.37 undefined
5/15/202539.64 undefined
5/14/202538.81 undefined
5/13/202539.51 undefined
5/12/202542.28 undefined
5/9/202540.22 undefined
5/8/202542.88 undefined

Akero Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Akero Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Akero Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Akero Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Akero Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Akero Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Akero Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Akero Therapeutics’s growth potential.

Akero Therapeutics Revenue, EBIT and net profit per share

DateAkero Therapeutics RevenueAkero Therapeutics EBITAkero Therapeutics Net Income
2030e1.18 B undefined0 undefined671.78 M undefined
2029e619.65 M undefined-132.09 M undefined182.84 M undefined
2028e152.18 M undefined-394.84 M undefined-202.01 M undefined
2027e0 undefined-467.58 M undefined-327.98 M undefined
2026e0 undefined-409.49 M undefined-315.17 M undefined
2025e0 undefined-357.8 M undefined-280.27 M undefined
20240 undefined-285.42 M undefined-252.06 M undefined
20230 undefined-172.87 M undefined-151.76 M undefined
20220 undefined-115.16 M undefined-112.03 M undefined
20210 undefined-100.89 M undefined-100.78 M undefined
20200 undefined-80.15 M undefined-79.21 M undefined
20190 undefined-45.65 M undefined-43.76 M undefined
20180 undefined-13.78 M undefined-82.23 M undefined
20170 undefined-4.56 M undefined-4.78 M undefined

Akero Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
201720182019202020212022202320242025e2026e2027e2028e2029e2030e
000000000000.150.621.18
------------307.2490.63
--------------
00000000000000
-4-82-43-79-100-112-151-252-280-315-327-202182671
-1,950.00-47.5683.7226.5812.0034.8266.8911.1112.503.81-38.23-190.10268.68
27.0527.0515.0731.4634.8338.9852.5767.14000000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Akero Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Akero Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (k)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (M)
OTHER EQUITY (k)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (k)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
20172018201920202021202220232024
               
0.676136.4268.4188.3351.4550.01743.08
00000000
00000000
00000000
01.21.635.33.79.9527.3
0.677.2138271.4193.6355.1559.96770.38
0001.81.51.31.030.76
00000019.2854.75
00000000
00000000
00000000
0010020040010000
000.121.91.420.3155.51
0.677.2138.1273.4195.5356.5580.27825.89
               
5124.700000.010.01
00.040.260.470.480.751.111.58
-4.6-86.6-130.3-209.5-310.3-422.3-574.1-826.16
000000270948
00000000
0.474.7128.7258.7169.1326.6535.31750.11
0.11.40.93.46.787.049.03
0.218.39.718.411.112.0930.73
0010000000
00000000
00000000
0.32.49.313.125.119.119.1339.75
000009.524.9635.3
00000000
0001.51.31.40.870.72
0001.51.310.925.8436.02
0.32.49.314.626.43044.9775.77
0.777.1138273.3195.5356.6580.27825.89
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Akero Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Akero Therapeutics's financial health and stability.

Assets

Akero Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Akero Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Akero Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Akero Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES ()
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
-4-81-43-79-100-112-151
0000000
0000000
01629-4-6
076312214734
0000002
0000000
-4-4-35-70-79-92-145
0000000
0-5-71-942-63-223
0-5-71-942-63-223
0000000
00000915
585952031246339
585952030255353
-------
0000000
075-11122-3699-15
-4.38-4.63-35.63-70.95-79.68-92.52-145.37
0000000

Akero Therapeutics stock margins

The Akero Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Akero Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Akero Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Akero Therapeutics's sales revenue. A higher gross margin percentage indicates that the Akero Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Akero Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Akero Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Akero Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Akero Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Akero Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Akero Therapeutics Margin History

Akero Therapeutics Gross marginAkero Therapeutics Profit marginAkero Therapeutics EBIT marginAkero Therapeutics Profit margin
2030e0 %0 %56.88 %
2029e0 %-21.32 %29.51 %
2028e0 %-259.46 %-132.75 %
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
20240 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %

Akero Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Akero Therapeutics earnings per share therefore indicates how much revenue Akero Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Akero Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Akero Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Akero Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Akero Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Akero Therapeutics Revenue, EBIT and net profit per share

DateAkero Therapeutics Sales per ShareAkero Therapeutics EBIT per shareAkero Therapeutics Earnings per Share
2030e17.59 undefined0 undefined10.01 undefined
2029e9.23 undefined0 undefined2.72 undefined
2028e2.27 undefined0 undefined-3.01 undefined
2027e0 undefined0 undefined-4.89 undefined
2026e0 undefined0 undefined-4.69 undefined
2025e0 undefined0 undefined-4.17 undefined
20240 undefined-4.25 undefined-3.75 undefined
20230 undefined-3.29 undefined-2.89 undefined
20220 undefined-2.95 undefined-2.87 undefined
20210 undefined-2.9 undefined-2.89 undefined
20200 undefined-2.55 undefined-2.52 undefined
20190 undefined-3.03 undefined-2.9 undefined
20180 undefined-0.51 undefined-3.04 undefined
20170 undefined-0.17 undefined-0.18 undefined

Akero Therapeutics business model

Akero Therapeutics Inc is an advanced biotherapy company focused on the development and commercialization of medications to improve patient health. The company was founded in 2017 by five experienced pharmaceutical experts: Andrew Cheng, Timothy Lu, David D. Kirn, Scott Freeman, and Stuart Lockhart. Akero Therapeutics Inc is headquartered in Belmont, California, USA. The business model of Akero Therapeutics Inc is based on targeted biological therapy aiming to address unmet medical needs in various disease areas. The idea is to reduce the risk of diseases such as diabetes, chronic liver diseases, and metabolic disorders and improve the quality of life for patients through the development of innovative biological agents. Akero Therapeutics is dedicated to combating these diseases with groundbreaking therapeutic approaches. The company offers various divisions including product development, research and development, and commercial. Product development at Akero Therapeutics encompasses the discovery, development, clinical testing, and efficacy assessment of new biological agents. The research division continuously works on identifying new target molecules to develop innovative approaches in disease therapy. The commercial division of Akero Therapeutics is responsible for developing an appropriate marketing strategy to bring the biological agents to market readiness and to patients. One of the most well-known products of Akero Therapeutics is the medication Efruxifermin (EFX). It is a protein molecule developed for the treatment of patients with non-alcoholic fatty liver disease (NAFLD). NAFLD is a disease characterized by the accumulation of fat in the liver without the patient consuming alcohol during the day. Fatty liver disease is a growing public health issue and one of the most common liver diseases worldwide. Akero Therapeutics has developed an effective medication, EFX, which effectively reduces liver fat content. Another product currently in the clinical research phase at Akero Therapeutics is AKR-001. It is a medication for the treatment of patients with lipid metabolism disorders, including hypertriglyceridemia and homozygous familial hypercholesterolemia. Lipid metabolism disorders are characterized by high levels of triglycerides and cholesterol in the blood and increase a patient's risk for cardiovascular diseases. In summary, Akero Therapeutics is a clinical biotherapy company dedicated to the development of treatments for various chronic diseases. The company combines innovative research with strong entrepreneurial capabilities to explore, develop, and bring new biological agents to the market for disease therapy. Akero Therapeutics is on track to establish a strong presence in the biopharmaceutical industry and has the potential to improve the lives of millions of patients worldwide. Akero Therapeutics is one of the most popular companies on Eulerpool.com.

Akero Therapeutics SWOT Analysis

Strengths

Akero Therapeutics Inc has a strong portfolio of innovative drug candidates, backed by extensive research and development efforts. The company's pipeline demonstrates potential for addressing unmet medical needs and creating value for patients and healthcare providers.

Akero Therapeutics Inc benefits from a team of experienced and talented professionals, including renowned scientists and industry experts. Their expertise and collaborations provide the company with a competitive edge in developing effective therapies and navigating regulatory processes.

Weaknesses

Akero Therapeutics Inc is currently in the early stages of drug development, which poses inherent risks and uncertainties associated with clinical trials and regulatory approvals. Failure to meet endpoints or gain necessary approvals could impact the company's future prospects.

The company may face challenges in terms of securing sufficient funding for its research and development activities. Raising capital in a highly competitive and dynamic market can be a potential weakness for Akero Therapeutics Inc.

Opportunities

The growing prevalence of certain medical conditions presents significant market opportunities for Akero Therapeutics Inc. The company's drug candidates have the potential to address unmet needs and capture a share of the expanding market.

Strategic partnerships and collaborations can provide Akero Therapeutics Inc with access to additional resources, expertise, and distribution channels. Such alliances can enhance the company's ability to successfully develop and commercialize its drug candidates.

Threats

The pharmaceutical industry is highly competitive, with numerous established companies and emerging players. Akero Therapeutics Inc may face intense competition from larger pharmaceutical companies with greater financial resources and established market presence.

The success of Akero Therapeutics Inc is reliant on the successful completion of clinical trials and obtaining regulatory approvals. Delays or failures in these processes can significantly impact the company's timeline and ability to bring its drug candidates to market.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Akero Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Akero Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Akero Therapeutics shares outstanding

The number of shares was Akero Therapeutics in 2024 — This indicates how many shares 67.137 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Akero Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Akero Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Akero Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Akero Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Akero Therapeutics.

Akero Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2025-0.99 -0.9  (9.09 %)2025 Q1
12/31/2024-1.18 -0.99  (15.77 %)2024 Q4
9/30/2024-0.92 -1.05  (-13.96 %)2024 Q3
6/30/2024-0.92 -0.81  (11.64 %)2024 Q2
3/31/2024-0.97 -0.9  (7.4 %)2024 Q1
12/31/2023-0.88 -0.99  (-12.69 %)2023 Q4
9/30/2023-0.69 -0.71  (-2.17 %)2023 Q3
6/30/2023-0.64 -0.6  (6.34 %)2023 Q2
3/31/2023-0.69 -0.55  (19.75 %)2023 Q1
12/31/2022-0.81 -0.49  (39.8 %)2022 Q4
1
2
3

Eulerpool ESG Scorecard© for the Akero Therapeutics stock

Eulerpool World ESG Rating (EESG©)

49/ 100

🌱 Environment

46

👫 Social

57

🏛️ Governance

45

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Akero Therapeutics shareholders

%
Name
Stocks
Change
Date
10.98795 % Wellington Management Company, LLP7,376,961-519,67112/31/2024
10.21768 % RTW Investments L.P.6,859,823940,38812/31/2024
8.98798 % Janus Henderson Investors6,034,239-1,043,23912/31/2024
7.79601 % General Atlantic LLC5,233,989012/31/2024
7.64943 % BlackRock Institutional Trust Company, N.A.5,135,581130,57512/31/2024
6.31841 % T. Rowe Price Associates, Inc.4,241,976531,86912/31/2024
5.50111 % The Vanguard Group, Inc.3,693,26827,83012/31/2024
3.47938 % State Street Global Advisors (US)2,335,944-167,00212/31/2024
2.73960 % AllianceBernstein L.P.1,839,281-177,80712/31/2024
2.32306 % Geode Capital Management, L.L.C.1,559,631-11,38112/31/2024
1
2
3
4
5
...
10

Akero Therapeutics Executives and Management Board

Dr. Andrew Cheng

(57)
Akero Therapeutics President, Chief Executive Officer, Director (since 2018)
Compensation 8.83 M

Mr. William White

(51)
Akero Therapeutics Chief Financial Officer, Executive Vice President, Head - Corporate Development, Treasurer
Compensation 4.29 M

Dr. Timothy Rolph

(70)
Akero Therapeutics Chief Scientific Officer, Co-Founder
Compensation 3.49 M

Ms. Catriona Yale

(52)
Akero Therapeutics Chief Development Officer
Compensation 3.45 M

Dr. Jonathan Young

(54)
Akero Therapeutics Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Compensation 3.44 M
1
2
3

Akero Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Amgen Stock
Amgen
SupplierCustomer-0,81-0,90-0,40-0,74-0,430,27
1

Most common questions regarding Akero Therapeutics

What values and corporate philosophy does Akero Therapeutics represent?

Akero Therapeutics Inc represents a commitment to advancing transformative treatments for serious metabolic diseases. The company's corporate philosophy is centered around innovation, collaboration, and dedication to improving patient outcomes. Akero Therapeutics Inc aims to develop and commercialize therapies that address the underlying causes of metabolic disease, such as non-alcoholic steatohepatitis (NASH) and other related disorders. With a focus on scientific excellence, Akero Therapeutics Inc strives to deliver groundbreaking solutions that positively impact the lives of patients worldwide.

In which countries and regions is Akero Therapeutics primarily present?

Akero Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Akero Therapeutics achieved?

Akero Therapeutics Inc, a renowned pharmaceutical company, has accomplished several significant milestones. One notable achievement is the successful completion of its Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). As part of this trial, Akero Therapeutics Inc demonstrated positive outcomes by reducing liver fat and fibrosis in patients. Additionally, the company received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational drug AKR-001, highlighting its potential to address unmet medical needs in NASH treatment. These achievements portray Akero Therapeutics Inc as a promising player in the pharmaceutical industry, dedicated to advancing therapies for liver diseases.

What is the history and background of the company Akero Therapeutics?

Akero Therapeutics Inc., headquartered in San Francisco, California, is a clinical-stage biotechnology company focused on developing transformative treatments for serious metabolic diseases. Established in 2018, Akero aims to improve the lives of patients suffering from conditions such as non-alcoholic steatohepatitis (NASH) and other systemic metabolic disorders. The company's innovative approach involves utilizing the power of endocrine hormone FGF21 to address the underlying causes of these diseases. With a dedicated team of scientific experts and strong financial backing, Akero is committed to advancing novel therapies and bringing hope to patients worldwide.

Who are the main competitors of Akero Therapeutics in the market?

Some of the main competitors of Akero Therapeutics Inc in the market include companies like Madrigal Pharmaceuticals, Viking Therapeutics, and Intercept Pharmaceuticals.

In which industries is Akero Therapeutics primarily active?

Akero Therapeutics Inc is primarily active in the biotechnology industry.

What is the business model of Akero Therapeutics?

The business model of Akero Therapeutics Inc is focused on the development and commercialization of transformative treatments for patients with serious metabolic diseases. The company aims to provide innovative solutions through their proprietary discovery platform and strategic partnerships. Akero Therapeutics Inc focuses on addressing unmet medical needs in diseases such as non-alcoholic steatohepatitis (NASH) and other metabolic disorders. By utilizing their expertise in biology, chemistry, and clinical development, Akero Therapeutics Inc aims to deliver breakthrough therapies that improve the lives of patients worldwide.

What is the P/E ratio of Akero Therapeutics 2025?

The P/E ratio cannot be calculated for Akero Therapeutics at the moment.

What is the P/S ratio of Akero Therapeutics 2025?

The P/S cannot be calculated for Akero Therapeutics currently.

What is the Quality Investing of Akero Therapeutics?

The Quality Investing for Akero Therapeutics is 2/10.

What is the revenue of Akero Therapeutics 2025?

The revenue cannot currently be calculated for Akero Therapeutics.

How high is the profit of Akero Therapeutics 2025?

The expected Akero Therapeutics profit is -280.27 M USD.

What is the business model of Akero Therapeutics

The company Akero Therapeutics Inc develops biopharmaceutical products for the treatment of metabolic diseases. The company focuses mainly on the research and development of drugs for the treatment of non-alcoholic fatty liver disease (NAFLD), one of the most common metabolic diseases worldwide. The strategy of Akero Therapeutics is to utilize the activation of the G-protein-coupled receptor 119 (GPR119) to increase insulin release and regulate the behavior of liver cells and fat oxidation in the liver. One of the key products of Akero Therapeutics is AKR-001, a fibroblast growth factor 21 (FGF21) modified by fusion of Fc and aprotinin, which increases GPR119 activation and regulates the behavior of liver cells and fat oxidation. Akero Therapeutics also utilizes a proprietary technology platform to identify biomarkers to optimize patient selection and facilitate the development of products in the pipeline. This is intended to expedite the approval of drugs and improve their efficacy. In addition to discovering new drugs, Akero Therapeutics collaborates closely with health authorities, academics, and patient organizations to raise awareness of metabolic diseases and support patients in the early detection and treatment of NAFLD. The business activities of Akero Therapeutics also include a partnership with Japan Tobacco Inc, which provides the company with financial resources to advance drug development. The company also actively solicits investors to invest in the research and development of new products. In summary, Akero Therapeutics is an innovative biopharmaceutical company focused on the research and development of drugs for the treatment of metabolic diseases. Through the utilization of a proprietary technology platform and partnerships with global health authorities, the company aims to bring to market drugs that meet the needs of patients and improve their lives.

What is the Akero Therapeutics dividend?

Akero Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Akero Therapeutics pay dividends?

The dividend cannot currently be calculated for Akero Therapeutics or the company does not pay out a dividend.

What is the Akero Therapeutics ISIN?

The ISIN of Akero Therapeutics is US00973Y1082.

What is the Akero Therapeutics WKN?

The WKN of Akero Therapeutics is A2PLNP.

What is the Akero Therapeutics ticker?

The ticker of Akero Therapeutics is AKRO.

How much dividend does Akero Therapeutics pay?

Over the past 12 months, Akero Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Akero Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Akero Therapeutics?

The current dividend yield of Akero Therapeutics is .

When does Akero Therapeutics pay dividends?

Akero Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Akero Therapeutics?

Akero Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Akero Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Akero Therapeutics located?

Akero Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Akero Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Akero Therapeutics from 6/7/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/7/2025.

When did Akero Therapeutics pay the last dividend?

The last dividend was paid out on 6/7/2025.

What was the dividend of Akero Therapeutics in the year 2024?

In the year 2024, Akero Therapeutics distributed 0 USD as dividends.

In which currency does Akero Therapeutics pay out the dividend?

The dividends of Akero Therapeutics are distributed in USD.

All fundamentals about Akero Therapeutics

Our stock analysis for Akero Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Akero Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.